Poison control center experience with tianeptine: an unregulated pharmaceutical product with potential for abuse
- PMID: 29799284
- DOI: 10.1080/15563650.2018.1476694
Poison control center experience with tianeptine: an unregulated pharmaceutical product with potential for abuse
Abstract
Background: Interest in tianeptine as a potential drug of abuse is increasing in the United States. We performed a retrospective study of calls to the New York State Poison Control Centers (PCCs) designed to characterize one state's experience with tianeptine. Methods: Data were gathered from existing records utilizing the poison center data collection system, Toxicall® entered between 1 January 2000 through 1 April 2017. Information regarding patient demographics, reported dose and formulation of tianeptine, reported coingestants, brief narrative description of the case, disposition, and case outcome was collected. Results: There were nine reported cases of tianeptine exposure. Seven were male with a mean age of 27. Three reported therapeutic use of tianeptine and five reported intentional abuse. One case was an unintentional pediatric exposure. Doses were reported in three cases; 12.5 mg in a pediatric unintentional exposure, and 5 and 10 g daily in the two reports of intentional abuse. Of note, five patients complained of symptoms consistent with opioid withdrawal. In one of two cases in which naloxone was administered, an improvement in mental status and the respiratory drive was noted. Outcomes reported in Toxicall® were minor in two cases, moderate in five cases, major in one case, and not reported in one case. Conclusions: These cases, reported to the New York State PCCs should alert readers to the potential for tianeptine abuse, dependence, and withdrawal.
Keywords: Tianeptine; addiction; opioids; withdrawal.
Similar articles
-
Characteristics of Tianeptine Exposures Reported to the National Poison Data System - United States, 2000-2017.MMWR Morb Mortal Wkly Rep. 2018 Aug 3;67(30):815-818. doi: 10.15585/mmwr.mm6730a2. MMWR Morb Mortal Wkly Rep. 2018. PMID: 30070980 Free PMC article.
-
Characteristics of tianeptine effects reported to a poison control center: a growing threat to public health.Clin Toxicol (Phila). 2021 Feb;59(2):152-157. doi: 10.1080/15563650.2020.1781151. Epub 2020 Jun 18. Clin Toxicol (Phila). 2021. PMID: 32552075
-
Tianeptine Abuse and Dependence in Psychiatric Patients: A Review of 18 Case Reports in the Literature.J Psychoactive Drugs. 2018 Jul-Aug;50(3):275-280. doi: 10.1080/02791072.2018.1438687. Epub 2018 Mar 1. J Psychoactive Drugs. 2018. PMID: 29494783 Review.
-
Use of Buprenorphine-Naloxone in the Treatment of Tianeptine Use Disorder.J Addict Med. 2019 Jul/Aug;13(4):331-333. doi: 10.1097/ADM.0000000000000490. J Addict Med. 2019. PMID: 30550394
-
Tianeptine Abuse and Dependence: Case Report and Literature Review.Psychosomatics. 2018 Nov;59(6):547-553. doi: 10.1016/j.psym.2018.07.006. Epub 2018 Jul 19. Psychosomatics. 2018. PMID: 30149933 Review.
Cited by
-
Misuse, Abuse and Medication Errors' Adverse Events Associated with Opioids-A Systematic Review.Pharmaceuticals (Basel). 2024 Jul 31;17(8):1009. doi: 10.3390/ph17081009. Pharmaceuticals (Basel). 2024. PMID: 39204114 Free PMC article. Review.
-
Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.J Anal Toxicol. 2022 Jul 14;46(6):e116-e185. doi: 10.1093/jat/bkac023. J Anal Toxicol. 2022. PMID: 35445267 Free PMC article. Review.
-
From Antidepressant Tianeptine to Street Drug ZaZa: A Narrative Review.Cureus. 2023 Jun 20;15(6):e40688. doi: 10.7759/cureus.40688. eCollection 2023 Jun. Cureus. 2023. PMID: 37485121 Free PMC article. Review.
-
Interpol review of controlled substances 2016-2019.Forensic Sci Int Synerg. 2020 May 24;2:608-669. doi: 10.1016/j.fsisyn.2020.01.019. eCollection 2020. Forensic Sci Int Synerg. 2020. PMID: 33385148 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous